Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer

被引：2

作者：

Arasanz, Hugo ^{[1
,2
]}

Chocarro, Luisa ^{[3
]}

Fernandez-Rubio, Leticia ^{[3
]}

Blanco, Ester ^{[3
,4
]}

Bocanegra, Ana ^{[3
]}

Echaide, Miriam ^{[3
]}

Labiano, Ibone ^{[2
]}

Huerta, Ana Elsa ^{[2
]}

Alsina, Maria ^{[1
,2
]}

Vera, Ruth ^{[1
,2
]}

Escors, David ^{[3
]}

Kochan, Grazyna ^{[3
]}

机构：

[1] Hosp Univ Navarra, Med Oncol Dept, Inst Invest Sanitaria Navarra IdiSNA, Pamplona 31008, Spain

[2] Inst Invest Sanitaria Navarra IdiSNA, Oncobiona Grp, Navarrabiomed, Pamplona 31008, Spain

[3] Inst Invest Sanitaria Navarra IdiSNA, Oncoimmunol Grp, Navarrabiomed, Pamplona 31008, Spain

[4] Inst Invest Sanitaria Navarra IdiSNA, Div Gene Therapy & Regulat Gene Express, Ctr Invest Med Aplicada CIMA, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2023年 / 24卷 / 12期

关键词：

lung cancer; bispecific; nanobodies; NSCLC; SCLC; targeted therapies; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; OPEN-LABEL; CHEMOTHERAPY; VEMURAFENIB; COBIMETINIB; MECHANISMS; NANOBODIES; NIVOLUMAB;

D O I：

10.3390/ijms24129855

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Bispecific antibodies are a promising type of therapy for the treatment of cancer due to their ability to simultaneously inhibit different proteins playing a role in cancer progression. The development in lung cancer has been singularly intense because of the increasingly vast knowledge of the underlying molecular routes, in particular, in oncogene-driven tumors. In this review, we present the current landscape of bispecific antibodies for the treatment of lung cancer and discuss potential scenarios where the role of these therapeutics might expand in the near future.

引用

页数：12

共 50 条

[31] Current Indications For Surgical Treatment of Lung Metastases
Freixinet, Jorge
Embun, Raul
Rodriguez, Pedro
ARCHIVOS DE BRONCONEUMOLOGIA, 2017, 53 (12): : 661 - 662
[32] Radiotherapy treatment for lung cancer: Current status and future directions
Vinod, Shalini K.
Hau, Eric
RESPIROLOGY, 2020, 25 : 61 - 71
[33] Lung cancer: an update on current and future diagnostic and treatment techniques
Zarogoulidis, Paul
Tsakiridis, Kosmas
Zarogoulidis, Konstantinos
JOURNAL OF THORACIC DISEASE, 2013, 5 : S341 - S341
[34] The Future Role of Bispecific Antibodies in Lymphoma
Allan, John N.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (08) : 500 - 502
[35] Antibody Drug Conjugates in Lung Cancer: State of the Current Therapeutic Landscape and Future Developments
Reuss, Joshua E.
Gosa, Laura
Liu, Stephen, V
CLINICAL LUNG CANCER, 2021, 22 (06) : 483 - 499
[36] Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Lim, Sun Min
Hong, Min Hee
Kim, Hye Ryun
IMMUNE NETWORK, 2020, 20 (01)
[37] Evolving treatment landscape of immunotherapy in breast cancer: current issues and future perspectives
Valenza, Carmine
Rizzo, Graziella
Passalacqua, Maria Ilenia
Boldrini, Laura
Corti, Chiara
Trapani, Dario
Curigliano, Giuseppe
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
[38] Multidisciplinary team diagnosis and treatment of pancreatic cancer: Current landscape and future prospects
Yao, Weirong
Chen, Xiaoliang
Fan, Bin
Zeng, Lin
Zhou, Zhiyong
Mao, Zhifang
Shen, Qinglin
FRONTIERS IN ONCOLOGY, 2023, 13
[39] Current and Future Landscape of Perioperative Treatment for Muscle-Invasive Bladder Cancer
Esteban-Villarrubia, Jorge
Torres-Jimenez, Javier
Bueno-Bravo, Carolina
Garcia-Mondaray, Rebeca
Subiela, Jose Daniel
Gajate, Pablo
CANCERS, 2023, 15 (03)
[40] Bispecific antibodies revolutionizing breast cancer treatment: a comprehensive overview
Lan, Huan-Rong
Chen, Min
Yao, Shi-Ya
Chen, Jun-Xia
Jin, Ke-Tao
FRONTIERS IN IMMUNOLOGY, 2023, 14

← 1 2 3 4 5 →